TGX 221

06/04/2012 - "Recent studies showed that TGX-221 has antiproliferative activity against PTEN-deficient tumor cell lines including prostate cancers. "
06/06/2011 - "The objective of this present study is to develop a peptide-drug conjugate to specifically deliver TGX-221 to HER2 overexpressing prostate cancer cells. "
06/04/2012 - "Prodrug strategy for PSMA-targeted delivery of TGX-221 to prostate cancer cells."
06/06/2011 - "TGX-221 is a highly potent phosphoinositide 3-kinase β (PI3Kβ) inhibitor that holds great promise as a novel chemotherapeutic agent to treat prostate cancer. "

11/01/2017 - "Collectively, our study revealed that TGX-221 could inhibit proliferation and induce apoptosis in glioblastoma cells."
11/01/2017 - "Moreover, migration and invasion assays revealed that TGX-221 inhibited human glioblastoma cell migration and invasion. "
11/01/2017 - "These results demonstrated that TGX-221 induced apoptosis in glioblastoma cells. "
11/01/2017 - "We performed a Cell Counting Kit-8 (CCK-8) test, EDU staining and cell cycle distribution analysis and found that TGX-221 inhibited glioblastoma cell proliferation. "
11/01/2017 - "We treated U87 and U251 glioblastoma cells with TGX-221 to determine the effect of TGX-221. "

01/01/2020 - "Subsequently, we screened out AKR1B10 and SPP1 sensitive molecules TGX-221, which may provide a possible therapy for NAFLD and NAFLD-HCC."

01/01/2021 - "Topical Application of the PI3Kβ-Selective Small Molecule Inhibitor TGX-221 Is an Effective Treatment Option for Experimental Epidermolysis Bullosa Acquisita."

11/21/2014 - "In vitro, PIK3CB expression was upregulated in all four colorectal cancer cell lines concurrently treated with 6-Gy ionizing radiation, and the PIK3CB-specific inhibitor TGX-221 effectively inhibited the clonogenic formation of these four colorectal cancer cell lines. "
11/21/2014 - "Pharmacological assays were used to evaluate the therapeutic relevance of TGX-221 (a PIK3CB-specific inhibitor) in the four colorectal cancer cell lines. "